Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates

Executive Summary

Agency memo on manufacturer communications about unapproved uses says new court rulings and studies on off-label uses and adverse reactions support restrictions; whether agency’s new leadership has the same view remains to be seen.


Related Content

US FDA Advertising Citations Remain Rare In 2018
Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
Off-Label Communications: Near-Term ‘Seismic Shift’ In FDA Oversight Unlikely
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Off-Label Communication: When Does It Align With Approved Labeling?
US FDA Clarifies ‘Intended Use’ Policy For Approved Products
Off-Label Communications: Industry, FDA Debate Role Of Peer Review
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts